livn-20210728

0001639691-21-000085.txt : 20210728 0001639691-21-000085.hdr.sgml : 20210728 20210728060307 ACCESSION NUMBER: 0001639691-21-000085 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210728 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210728 DATE AS OF CHANGE: 20210728 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LivaNova PLC CENTRAL INDEX KEY: 0001639691 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 981268150 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37599 FILM NUMBER: 211119708 BUSINESS ADDRESS: STREET 1: 20 EASTBOURNE TERRACE CITY: LONDON STATE: X0 ZIP: W2 6LG BUSINESS PHONE: 4402033250662 MAIL ADDRESS: STREET 1: 20 EASTBOURNE TERRACE CITY: LONDON STATE: X0 ZIP: W2 6LG FORMER COMPANY: FORMER CONFORMED NAME: Sand Holdco Plc DATE OF NAME CHANGE: 20150420 FORMER COMPANY: FORMER CONFORMED NAME: Sand Holdco Ltd DATE OF NAME CHANGE: 20150415 8-K 1 livn-20210728.htm LIVANOVA 8-K Q2 2021 EARNINGS RELEASE livn-20210728

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 28, 2021

LivaNova PLC

(Exact Name of Registrant as Specified in its Charter)

England and Wales

001-37599

98-1268150

(State or Other Jurisdiction
of Incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

20 Eastbourne Terrace

London, W2 6LG

United Kingdom

(Address of Principal Executive Offices)

+44 20 33250660

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name on each exchange on which registered
Ordinary Shares - £1.00 par value per share	LIVN	NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


			Emerging growth company			☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


						☐

Item 2.02 Results of Operations and Financial Condition

On July 28, 2021, LivaNova PLC (the "Company") issued a press release announcing financial results for the second quarter ended June 30, 2021. The Company will host a business update conference call and webcast today, July 28, 2021, at 1 p.m. London time (8 a.m. Eastern Daylight Time), during which the Company will discuss the financial results. The conference call will be available to interested parties through a live audio webcast and accessible through the Investors section of the LivaNova website at www.livanova.com.

A copy of the Company’s press release related to the foregoing matters is attached hereto as Exhibit 99.1. The information in Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended or the Exchange Act, regardless of any general incorporation language contained in such filing, unless otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.


Exhibit						Description

99.1						Press Release of LivaNova PLC dated July 28, 2021
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			LivaNova PLC


Date: July 28, 2021			By:/s/ Keyna Skeffington
			Name: Keyna Skeffington
			Title: Senior Vice President & General Counsel

EX-99.1 2 a2q2021earningspressrelease.htm LIVANOVA PRESS RELEASE DATED JULY 28, 2021 Document

EXHIBIT 99.1

NEWS RELEASE

LivaNova Reports Second Quarter 2021 Results and

Appoints Alex Shvartsburg as Chief Financial Officer

London, July 28, 2021 – LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2021.

For the second quarter of 2021, worldwide sales from continuing operations were $264.5 million, an increase of 45.2 percent on a reported basis and 41.0 percent on a constant-currency1 basis, as compared to the same quarter of the previous year. Worldwide sales from continuing operations for the second quarter of 2021, excluding sales related to the Heart Valves business that was divested effective June 1 as part of the initial closing, were $249.8 million, an increase of 51.6 percent on a reported basis and 47.6 percent on a constant-currency1 basis, as compared to the same quarter of the previous year. On the basis of U.S. Generally Accepted Accounting Principles (GAAP), second quarter 2021 diluted loss per share from continuing operations was $1.13. Second quarter 2021 adjusted diluted earnings per share from continuing operations was $0.52.

“As we navigate shifting market dynamics resulting from the pandemic, we continue to gain momentum in Epilepsy sales growth across all regions,” said Damien McDonald, Chief Executive Officer of LivaNova. “Procedure volumes in Neuromodulation continue to recover, especially replacement implant volumes. Across our businesses, certain countries in our Europe and Rest of World regions remain challenged by COVID-19. Looking ahead, we are focused on delivering critical medical devices and therapies to significant patient populations, while managing our core businesses to drive profitability and cash generation. We also remain committed to investing in our pipeline and taking the appropriate actions to position our business for long-term growth.”

1Constant-currency percent change is a non-GAAP metric. For an explanation of this and other non-GAAP metrics used in this release, please see the section entitled "Use of Non-GAAP Financial Measures." For reconciliations of certain non-GAAP metrics, please see the tables that accompany the press release.

Second Quarter 2021 Results

The following table summarizes worldwide sales for the second quarter of 2021 by business:


$ in millions	Three Months Ended June 30,		% Change		Constant-Currency % Change
Business / Product Line:	2021	2020
Cardiopulmonary	$117.9	$101.1	16.6	%	12.1	%
Heart Valves	14.7	17.5	(15.7)	%	(21.5)	%
Advanced Circulatory Support	13.3	6.0	120.8	%	120.3	%
Cardiovascular	145.9	124.5	17.1	%	12.6	%
Neuromodulation	117.6	57.2	105.6	%	102.4	%
Other	1.0	0.5	111.8	%	N/A
Total Net Sales	$264.5	$182.2	45.2	%	41.0	%


Total Net Sales, Excluding Heart Valves			$249.8			$164.7			51.6		%	47.6		%

•Note: Numbers may not add precisely due to rounding. Constant-currency percent change and Total Net Sales, Excluding Heart Valves are non-GAAP metrics. For an explanation of these and other non-GAAP metrics used in this release, please see the section entitled "Use of Non-GAAP Financial Measures." For reconciliations of certain non-GAAP metrics, please see the tables that accompany the press release.

All sales growth rates below reflect comparable, constant-currency growth. Constant-currency growth accounts for the impact from fluctuations in the various currencies in which the Company operates as compared to reported growth.

Cardiovascular

Cardiovascular sales, which include Cardiopulmonary, Heart Valves and Advanced Circulatory Support (ACS) products, were $145.9 million, representing a 12.6 percent increase versus the second quarter of 2020.

Sales in Cardiopulmonary products were $117.9 million, representing a 12.1 percent increase versus the second quarter of 2020. The sales increase was primarily related to growth in oxygenators, largely in the Europe and U.S. regions, partially offset by a reduction in capital equipment purchases in the Rest of World region.

Heart Valve sales were $14.7 million, a decrease of 21.5 percent compared to sales of $17.5 million in the second quarter of 2020, representing a full quarter of sales. This decrease is related to the impact of the Heart Valves business divestiture that was effective June 1 as part of the initial closing.

ACS sales were $13.3 million in the quarter, an increase of 120.3 percent compared to the second quarter of 2020, due to the continued adoption of LifeSPARC® in the U.S. and an increase in procedure volumes.

Neuromodulation

Neuromodulation sales were $117.6 million in the second quarter, representing a 102.4 percent increase versus the second quarter of 2020. This increase reflects improving market dynamics across all regions, particularly in the U.S.

Financial Performance

On a U.S. GAAP basis, second quarter 2021 operating loss from continuing operations was $34.9 million. Adjusted operating income from continuing operations for the second quarter of 2021 was $39.3 million, as compared to an adjusted operating loss from continuing operations for the second quarter of 2020 of $4.2 million. This increase was primarily driven by favorable sales results and margin improvements.

On a U.S. GAAP basis, second quarter 2021 effective tax rate was a negative 8.1 percent, as compared to a negative 306.0 percent in the second quarter of 2020. The adjusted effective tax rate in the quarter was 14.7 percent, as compared to 2.8 percent in the second quarter of 2020, related to changes in the geographic income mix.

On a U.S. GAAP basis, second quarter 2021 diluted loss per share from continuing operations was $1.13. Second quarter 2021 adjusted diluted earnings per share from continuing operations was $0.52, as compared to a loss of $0.15 per share in the second quarter of 2020.

2021 Updated Guidance

Based upon our performance in the first half of 2021, LivaNova worldwide net sales from continuing operations for full-year 2021 are expected to grow between 5 and 10 percent on a constant-currency basis. Adjusted diluted earnings per share from continuing operations for 2021 are expected to be in the range of $1.60 to $1.90. In 2021, the Company estimates that adjusted free cash flow will be in the range of $35 to $55 million.

Appointment of Chief Financial Officer

LivaNova announced today that it has appointed Alex Shvartsburg to the role of Chief Financial Officer (CFO) effective August 1. Shvartsburg has served as interim CFO of LivaNova since October 31, 2020 and brings over 25 years of relevant industry experience, serving in roles across global corporate finance, planning and analysis, mergers and acquisitions and treasury. The appointment follows a formal search that was led by Egon Zehnder, an internationally recognized global leadership advisory firm.

“On behalf of the Board of Directors and executive leadership team at LivaNova, we are pleased to officially welcome Alex as the CFO,” said McDonald. “Alex is deeply familiar with our company’s strategy and business and has been instrumental in effecting cost-containment measures, strategically allocating resources, driving margin expansion and improving cash generation. We look forward to his continued contribution and perspective as a part of our leadership team.”

“I believe LivaNova is poised to realize its full potential with its leading Cardiovascular and Neuromodulation platforms. I am eager to play a leadership role in creating value for all of our stakeholders,” said Shvartsburg.

Webcast and Conference Call Instructions

The Company will host a live audio webcast for interested parties commencing at 1 p.m. London time (8 a.m. Eastern Daylight Time) on Wednesday, July 28 that will be accessible through the Investors section of the LivaNova website at www.livanova.com. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial 844-558-0159 (if dialing from within the U.S. or Canada) or 236-714-3182 (if dialing from outside the U.S. or Canada). The conference ID is 3308297. Within 24 hours of the webcast, a replay will be available under the "News / Events & Presentations" section of the Investors portion of the LivaNova website, where it will be archived and accessible for approximately 90 days.

About LivaNova

LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 3,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.

Use of Non-GAAP Financial Measures

In this press release, management has disclosed financial measurements that present financial information not necessarily in accordance with GAAP. Company management uses these measurements as aids in monitoring the Company’s ongoing financial performance from quarter to quarter and year to year on a regular basis and for benchmarking against other medical technology companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP.

Unless otherwise noted, all sales growth rates in this release reflect comparable, constant-currency growth. Management believes that referring to comparable, constant-currency growth is the most useful way to evaluate the sales performance of LivaNova and to compare the sales performance of current periods to prior periods on a consistent basis. Constant-currency growth, a non-GAAP financial measure, measures the change in sales between current and prior-year periods using average exchange rates in effect during the applicable prior-year period.

LivaNova calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For example, forward-looking net sales growth projections are estimated on a constant-currency basis and exclude the impact of foreign currency fluctuations. Forward-looking non-GAAP adjusted tax rate and adjusted diluted earnings per share guidance exclude other items such as, but not limited to, changes in fair value of contingent consideration arrangements, asset impairment charges and product remediation costs that would be included in comparable GAAP financial measures. The most directly comparable GAAP measure for constant-currency net sales, non-GAAP adjusted tax rate and adjusted diluted earnings per share are net sales, the effective tax rate and earnings per share, respectively. However, non-GAAP financial adjustments on a forward-looking basis are subject to uncertainty and variability as they are dependent on many factors, including but not limited to, the effect of foreign currency exchange fluctuations, impacts from potential acquisitions or divestitures, gains or losses on the potential sale of businesses or other assets, restructuring costs, merger and integration activities, changes in fair value of contingent consideration arrangements, product remediation costs, asset impairment charges, and the tax impact of the aforementioned items, tax law changes or other tax matters. Accordingly, reconciliations to the most directly comparable forward-looking GAAP financial measures are not available without unreasonable effort.

The Company also believes adjusted financial measures such as adjusted gross profit percentage, adjusted selling, general and administrative expense, adjusted research and development expense, adjusted other operating expenses, adjusted operating income from continuing operations, adjusted segment operating income, adjusted income tax expense, adjusted net income from continuing operations, and adjusted diluted earnings per share from continuing operations, are measures by which LivaNova generally uses to facilitate management review of the operational performance of the company, to serve as a basis for strategic planning and to assist in the design of compensation incentive plans. Furthermore, adjusted financial measures allow investors to evaluate the Company’s core performance for different periods on a more comparable and consistent basis, and with other entities in the medical technology industry by adjusting for items that are not related to the ongoing operations of the Company or incurred in the ordinary course of business.

Safe Harbor Statement

Certain statements in this press release, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, LivaNova’s plans, objectives, strategies, appointments, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, our actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee,” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by LivaNova and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning achieving a stronger future, driving sustainable growth and value to our shareholders, projected net sales, adjusted diluted earnings per share, cash flow from operations, capital expenditures, and depreciation and amortization for 2021, advancing our growth, driving product launches and funding our equity investments, executing on our synergy targets and retaining our focus, energy and discipline as a company, and serving the needs of our customers and patients. Important factors that may cause actual results to differ include, but are not limited to: (i) the severity and duration of the COVID-19 pandemic and its impact on our business, financial condition and results of

operations; (ii) reductions in customer spending, a slowdown in customer payments and changes in customer demand for products and services; (iii) unanticipated changes relating to competitive factors in the industries in which LivaNova operates; (iv) the ability to hire and retain key personnel; (v) the ability to attract new customers and retain existing customers in the manner anticipated; (vi) changes in legislation or governmental regulations affecting LivaNova; (vii) international, national or local economic, social or political conditions that could adversely affect LivaNova, its partners or its customers; (viii) conditions in the credit markets; (ix) business and other financial risks inherent to the industries in which LivaNova operates; (x) risks associated with assumptions made in connection with critical accounting estimates and legal proceedings; (xi) LivaNova’s international operations, which are subject to the risks of currency fluctuations and foreign exchange controls; (xii) the potential for international unrest, economic downturn or effects of currencies, tax assessments, tax adjustments, anticipated tax rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs; (xiii) the inability of LivaNova to meet expectations regarding the timing, completion and accounting of tax treatments; and (xiv) organizational and governance structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the United States Securities and Exchange Commission by LivaNova.

We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this press release. The Company does not undertake or assume any obligation to update publicly any of the forward-looking statements in this press release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.


Lindsey Little Senior Director, Investor Relations Phone: +1 281-895-2382 e-mail: InvestorRelations@livanova.com


LIVANOVA PLC
NET SALES
(U.S. dollars in millions)
		Three Months Ended June 30,
		2021	2020	% Change at Actual Currency Rates		% Change at Constant-Currency Rates (1)
Cardiopulmonary
US		$37.4	$25.8	44.8	%	44.8	%
Europe		35.1	23.3	50.8	%	37.7	%
Rest of World		45.4	51.9	(12.7)	%	(15.6)	%
Total		117.9	101.1	16.6	%	12.1	%
Heart Valves
US		2.2	2.5	(11.1)	%	(11.1)	%
Europe		6.1	5.3	14.5	%	3.2	%
Rest of World		6.4	9.6	(33.7)	%	(37.9)	%
Total		14.7	17.5	(15.7)	%	(21.5)	%
Advanced Circulatory Support
US		13.0	5.7	128.7	%	128.7	%
Europe		0.2	0.3	NM		NM
Rest of World		0.1	—	NM		NM
Total		13.3	6.0	120.8	%	120.3	%
Cardiovascular
US		52.6	34.0	54.7	%	54.7	%
Europe		41.4	28.9	43.1	%	30.4	%
Rest of World		51.9	61.6	(15.8)	%	(18.9)	%
Total		145.9	124.5	17.1	%	12.6	%
Neuromodulation
US		91.8	44.2	107.6	%	107.6	%
Europe		14.6	6.4	127.6	%	104.8	%
Rest of World		11.3	6.6	71.0	%	65.1	%
Total		117.6	57.2	105.6	%	102.4	%
Other
US		—	—	N/A		N/A
Europe		—	—	N/A		N/A
Rest of World		1.0	0.5	111.8	%	N/A
Total		1.0	0.5	111.8	%	N/A
Totals
US		144.3	78.2	84.6	%	84.6	%
Europe		56.0	35.4	58.5	%	43.9	%
Rest of World		64.1	68.7	(6.6)	%	(10.1)	%
Total		$264.5	$182.2	45.2	%	41.0	%

(1)	Constant-currency growth, a non-GAAP financial measure, measures the change in sales between current and prior-year periods using average exchange rates in effect during the applicable prior-year period.
*	The sales results presented are unaudited. Numbers may not add precisely due to rounding.


LIVANOVA PLC
NET SALES
(U.S. dollars in millions)
		Six Months Ended June 30,
		2021	2020	% Change at Actual Currency Rates		% Change at Constant-Currency Rates (1)
Cardiopulmonary
US		$73.1	$62.7	16.7	%	16.7	%
Europe		65.8	57.5	14.3	%	4.6	%
Rest of World		87.7	97.2	(9.8)	%	(13.1)	%
Total		226.6	217.4	4.2	%	0.2	%
Heart Valves
US		4.9	5.9	(15.9)	%	(15.9)	%
Europe		14.4	14.9	(3.2)	%	(11.8)	%
Rest of World		16.8	21.9	(23.2)	%	(26.9)	%
Total		36.2	42.7	(15.2)	%	(20.1)	%
Advanced Circulatory Support
US		25.5	15.7	62.1	%	62.1	%
Europe		0.4	0.7	NM		NM
Rest of World		0.3	0.1	NM		NM
Total		26.3	16.5	59.2	%	58.8	%
Cardiovascular
US		103.6	84.3	22.9	%	22.9	%
Europe		80.6	73.1	10.3	%	0.8	%
Rest of World		104.9	119.2	(12.1)	%	(15.4)	%
Total		289.0	276.6	4.5	%	0.5	%
Neuromodulation
US		174.1	117.5	48.2	%	48.2	%
Europe		26.3	17.0	54.6	%	40.3	%
Rest of World		21.0	12.4	69.4	%	66.9	%
Total		221.3	146.9	50.7	%	48.8	%
Other
US		—	—	N/A		N/A
Europe		—	—	N/A		N/A
Rest of World		1.7	1.1	51.3	%	N/A
Total		1.7	1.1	51.3	%	N/A
Totals
US		277.7	201.8	37.6	%	37.6	%
Europe		106.9	90.1	18.6	%	8.3	%
Rest of World		127.6	132.8	(3.9)	%	(7.3)	%
Total		$512.1	$424.6	20.6	%	17.3	%

(1)	Constant-currency growth, a non-GAAP financial measure, measures the change in sales between current and prior-year periods using average exchange rates in effect during the applicable prior-year period.
*	The sales results presented are unaudited. Numbers may not add precisely due to rounding.


LIVANOVA PLC AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - UNAUDITED
(U.S. dollars in millions, except per share amounts)

	Three Months Ended June 30,
	2021	2020	% Change
Net sales	$264.5	$182.2
Cost of sales	90.8	65.7
Gross profit	173.7	116.5	49.1	%
Operating expenses:
Selling, general and administrative	122.7	102.7
Research and development	52.6	25.2




Other operating expenses	33.2	3.8
Operating loss from continuing operations	(34.9)	(15.2)	128.8	%
Interest expense, net	(16.3)	(5.4)
Foreign exchange and other gains (losses)	0.1	(1.0)
Loss from continuing operations before tax	(51.1)	(21.7)	136.0	%
Income tax expense	4.1	66.3

Net loss from continuing operations	(55.3)	(88.0)	(37.1)	%
Net loss from discontinued operations, net of tax	—	—
Net loss	($55.3)	($88.0)	(37.1)	%

Basic loss per share:
Continuing operations	($1.13)	($1.81)
Discontinued operations	—	—
	($1.13)	($1.81)

Diluted loss per share:
Continuing operations	($1.13)	($1.81)
Discontinued operations	—	—
	($1.13)	($1.81)

Weighted average common shares outstanding:
Basic	48.9	48.6
Diluted	48.9	48.6

* Numbers may not add precisely due to rounding.


Adjusted Financial Measures (U.S. dollars in millions, except per share amounts)

		Three Months Ended June 30,
		2021	2020	% Change (1)
Adjusted SG&A (1)		$101.5	$79.7	27.4	%
Adjusted R&D (1)		43.6	35.2	23.8	%
Adjusted operating income (loss) from continuing operations (1)		39.3	(4.2)	(1,035.5)	%
Adjusted net income (loss) from continuing operations (1)		25.7	(7.5)	(443.5)	%
Adjusted diluted earnings per share from continuing operations (1)		$0.52	($0.15)	(435.1)	%

(1)	Adjusted financial measures are non-GAAP measures and exclude specified items as described and reconciled in the “Reconciliation of GAAP to non-GAAP Financial Measures” contained in the press release.


Statistics (as a % of net sales, except for income tax rate)

		GAAP Three Months Ended June 30,				Adjusted (1) Three Months Ended June 30,
		2021		2020		2021		2020
Gross profit		65.7	%	63.9	%	69.7	%	60.7	%
SG&A		46.4	%	56.4	%	38.4	%	43.7	%
R&D		19.9	%	13.8	%	16.5	%	19.3	%
Operating (loss) income from continuing operations		(13.2)	%	(8.4)	%	14.9	%	(2.3)	%
Net (loss) income from continuing operations		(20.9)	%	(48.3)	%	9.7	%	(4.1)	%
Income tax rate		(8.1)	%	(306.0)	%	14.7	%	2.8	%

(1)	Adjusted financial measures are non-GAAP measures and exclude specified items as described and reconciled in the “Reconciliation of GAAP to non-GAAP Financial Measures” contained in the press release.


LIVANOVA PLC AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - UNAUDITED
(U.S. dollars in millions, except per share amounts)

	Six Months Ended June 30,
	2021	2020	% Change
Net sales	$512.1	$424.6
Cost of sales	173.7	141.6
Gross profit	338.4	283.0	19.6	%
Operating expenses:
Selling, general and administrative	238.4	227.7
Research and development	97.2	61.1




Other operating expenses	42.0	8.9
Operating loss from continuing operations	(39.3)	(14.6)	168.5	%
Interest expense, net	(32.3)	(10.1)
Foreign exchange and other losses	(6.3)	(2.9)
Loss from continuing operations before tax	(77.9)	(27.7)	181.7	%
Income tax expense	7.0	21.6
Losses from equity method investments	(0.1)	(0.2)
Net loss from continuing operations	(85.0)	(49.4)	72.0	%
Net loss from discontinued operations, net of tax	—	(1.0)
Net loss	($85.0)	($50.4)	68.6	%

Basic loss per share:
Continuing operations	($1.74)	($1.02)
Discontinued operations	—	(0.02)
	($1.74)	($1.04)

Diluted loss per share:
Continuing operations	($1.74)	($1.02)
Discontinued operations	—	(0.02)
	($1.74)	($1.04)

Weighted average common shares outstanding:
Basic	48.8	48.5
Diluted	48.8	48.5

* Numbers may not add precisely due to rounding.


Adjusted Financial Measures (U.S. dollars in millions, except per share amounts)

		Six Months Ended June 30,
		2021	2020	% Change (1)
Adjusted SG&A (1)		$197.8	$183.4	7.8	%
Adjusted R&D (1)		85.5	76.1	12.3	%
Adjusted operating income from continuing operations (1)		70.9	16.8	321.9	%
Adjusted net income from continuing operations (1)		43.3	8.5	410.1	%
Adjusted diluted earnings per share from continuing operations (1)		$0.87	$0.17	400.6	%

(1)	Adjusted financial measures are non-GAAP measures and exclude specified items as described and reconciled in the “Reconciliation of GAAP to non-GAAP Financial Measures” contained in the press release.


Statistics (as a % of net sales, except for income tax rate)

		GAAP Six Months Ended June 30,				Adjusted (1) Six Months Ended June 30,
		2021		2020		2021		2020
Gross profit		66.1	%	66.6	%	69.2	%	65.1	%
SG&A		46.6	%	53.6	%	38.6	%	43.2	%
R&D		19.0	%	14.4	%	16.7	%	17.9	%
Operating (loss) income from continuing operations		(7.7)	%	(3.4)	%	13.8	%	4.0	%
Net (loss) income from continuing operations		(16.6)	%	(11.6)	%	8.4	%	2.0	%
Income tax rate		(9.0)	%	(78.0)	%	13.2	%	12.4	%

(1)	Adjusted financial measures are non-GAAP measures and exclude specified items as described and reconciled in the “Reconciliation of GAAP to non-GAAP Financial Measures” contained in the press release.


RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (U.S. dollars in millions, except per share amounts)
			Specified Items
Three Months Ended June 30, 2021	GAAP Financial Measures		Merger and Integration Expenses (A)		Restructuring Expenses (B)		Depreciation and Amortization Expenses (C)		Heart Valves (D)		Product Remediation Expenses (E)		Financing Transactions (F)		Certain Legal, Contingent Consideration and Other (G)		Stock-based Compensation Costs (H)		Certain Tax Adjustments (I)		Certain Interest Adjustments (J)		Adjusted Financial Measures
Cost of sales	$90.8		$—		$—		($3.9)		$—		($0.4)		$—		($5.2)		($1.1)		$—		$—		$80.1
Gross profit percent	65.7	%	—	%	—	%	1.5	%	—	%	0.1	%	—	%	2.0	%	0.4	%	—	%	—	%	69.7	%
Selling, general and administrative	122.7		—		—		(3.1)		—		—		—		(12.2)		(6.0)		—		—		101.5
Selling, general and administrative as a percent of net sales	46.4	%	—	%	—	%	(1.2)	%	—	%	—	%	—	%	(4.6)	%	(2.3)	%	—	%	—	%	38.4	%
Research and development	52.6		—		—		—		—		—		—		(6.3)		(2.8)		—		—		43.6
Research and development as a percent of net sales	19.9	%	—	%	—	%	—	%	—	%	—	%	—	%	(2.4)	%	(1.0)	%	—	%	—	%	16.5	%

Other operating expenses	33.2		(0.1)		(3.6)		—		(0.1)		—		—		(29.4)		—		—		—		—
Operating (loss) income from continuing operations	(34.9)		0.1		3.6		7.0		0.1		0.4		—		53.1		9.9		—		—		39.3
Operating margin percent	(13.2)	%	—	%	1.4	%	2.6	%	—	%	0.1	%	—	%	20.1	%	3.7	%	—	%	—	%	14.9	%
Income tax expense	4.1		—		0.2		0.5		3.6		0.1		—		(0.6)		0.3		(3.9)		—		4.4
Net (loss) income from continuing operations	(55.3)		0.1		3.4		6.4		(3.5)		0.3		5.7		50.5		9.6		3.9		4.6		25.7
Diluted EPS - Continuing Operations	($1.13)		$—		$0.07		$0.13		($0.07)		$0.01		$0.11		$1.01		$0.19		$0.08		$0.09		$0.52


GAAP results for the three months ended June 30, 2021 include:
(A)			Merger and integration expenses related to our legacy companies and recent acquisitions
(B)			Restructuring expenses related to organizational changes
(C)			Includes depreciation and amortization associated with purchase price accounting
(D)			Loss associated with the sale of Heart Valves
(E)			Costs related to the 3T Heater-Cooler remediation plan
(F)			Costs associated with our June 2020 financing transactions, including the mark-to-market adjustment for the exchangeable option feature and capped call derivatives
(G)			3T Heater-Cooler litigation provision, legal expenses primarily related to 3T Heater-Cooler defense, settlements, other matters, remeasurement of contingent consideration related to acquisitions and dividend income
(H)			Non-cash expenses associated with stock-based compensation costs
(I)			Primarily relates to discrete tax items
(J)			Primarily relates to non-cash interest expense on our Senior Secured Term Loan and Cash Exchangeable Senior Notes
* Numbers may not add precisely due to rounding.


RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (U.S. dollars in millions, except per share amounts)
			Specified Items
Three Months Ended June 30, 2020	GAAP Financial Measures		Merger and Integration Expenses (A)		Restructuring Expenses (B)		Depreciation and Amortization Expenses (C)		Product Remediation Expenses (D)		Financing Transactions (E)		Certain Legal, Contingent Consideration and Other (F)		Stock-based Compensation Costs (G)		Certain Tax Adjustments (H)		Certain Interest Adjustments (I)		Adjusted Financial Measures
Cost of sales	$65.7		$—		$—		($5.0)		($4.3)		$—		$15.4		($0.3)		$—		$—		$71.6
Gross profit percent	63.9	%	—	%	—	%	2.7	%	2.3	%	—	%	(8.5)	%	0.2	%	—	%	—	%	60.7	%
Selling, general and administrative	102.7		—		—		(4.8)		—		(2.5)		(6.5)		(9.3)		—		—		79.7
Selling, general and administrative as a percent of net sales	56.4	%	—	%	—	%	(2.6)	%	—	%	(1.4)	%	(3.6)	%	(5.1)	%	—	%	—	%	43.7	%
Research and development	25.2		—		—		—		—		—		10.5		(0.4)		—		—		35.2
Research and development as a percent of net sales	13.8	%	—	%	—	%	—	%	—	%	—	%	5.7	%	(0.2)	%	—	%	—	%	19.3	%
Other operating expenses	3.8		(2.0)		(0.8)		—		—		—		(1.0)		—		—		—		—
Operating loss from continuing operations	(15.2)		2.0		0.8		9.8		4.3		2.5		(18.4)		10.0		—		—		(4.2)
Operating margin percent	(8.4)	%	1.1	%	0.4	%	5.4	%	2.3	%	1.4	%	(10.1)	%	5.5	%	—	%	—	%	(2.3)	%
Income tax expense (benefit)	66.3		—		(0.2)		1.4		0.5		—		0.6		(0.4)		(67.9)		(0.5)		(0.2)
Net loss from continuing operations	(88.0)		2.0		1.0		8.4		3.8		2.7		(19.0)		10.4		67.9		3.3		(7.5)
Diluted EPS - Continuing Operations	($1.81)		$0.04		$0.02		$0.17		$0.08		$0.05		($0.39)		$0.21		$1.40		$0.07		($0.15)


GAAP results for the three months ended June 30, 2020 include:
(A)			Merger and integration expenses related to our legacy companies and recent acquisitions
(B)			Restructuring expenses related to organizational changes
(C)			Includes depreciation and amortization associated with purchase price accounting
(D)			Costs related to the 3T Heater-Cooler remediation plan
(E)			Costs associated with our June 2020 financing transactions, including the mark-to-market adjustment for the exchangeable option feature and capped call derivatives
(F)			3T Heater-Cooler litigation provision, legal expenses primarily related to 3T Heater-Cooler defense, settlements and other matters, remeasurement of contingent consideration related to acquisitions
(G)			Non-cash expenses associated with stock-based compensation costs
(H)			Primarily relates to discrete tax items and the tax impact of intercompany transactions
(I)			Primarily relates to non-cash interest expense on our Senior Secured Term Loan and Cash Exchangeable Senior Notes, interest related to the 3T Heater-Cooler matter and intellectual property migration
* Numbers may not add precisely due to rounding.


RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (U.S. dollars in millions, except per share amounts)
			Specified Items
Six Months Ended June 30, 2021	GAAP Financial Measures		Merger and Integration Expenses (A)		Restructuring Expenses (B)		Depreciation and Amortization Expenses (C)		Heart Valves (D)		Product Remediation Expenses (E)		Financing Transactions (F)		Certain Legal, Contingent Consideration and Other (G)		Stock-based Compensation Costs (H)		Certain Tax Adjustments (I)		Certain Interest Adjustments (J)		Adjusted Financial Measures
Cost of sales	$173.7		$—		$—		($7.9)		$—		($0.4)		$—		($5.6)		($1.8)		$—		$—		$157.9
Gross profit percent	66.1	%	—	%	—	%	1.5	%	—	%	0.1	%	—	%	1.1	%	0.3	%	—	%	—	%	69.2	%
Selling, general and administrative	238.4		—		—		(6.1)		—		—		—		(21.1)		(13.3)		—		—		197.8
Selling, general and administrative as a percent of net sales	46.6	%	—	%	—	%	(1.2)	%	—	%	—	%	—	%	(4.1)	%	(2.6)	%	—	%	—	%	38.6	%
Research and development	97.2		—		—		0.1		—		—		—		(7.5)		(4.3)		—		—		85.5
Research and development as a percent of net sales	19.0	%	—	%	—	%	—	%	—	%	—	%	—	%	(1.5)	%	(0.8)	%	—	%	—	%	16.7	%

Other operating expenses	42.0		(0.7)		(9.7)		—		0.8		—		—		(32.4)		—		—		—		—
Operating (loss) income from continuing operations	(39.3)		0.7		9.7		14.0		(0.8)		0.4		—		66.6		19.5		—		—		70.9
Operating margin percent	(7.7)	%	0.1	%	1.9	%	2.7	%	(0.2)	%	0.1	%	—	%	13.0	%	3.8	%	—	%	—	%	13.8	%
Income tax expense	7.0		—		0.3		1.1		3.7		0.1		—		—		0.5		(6.2)		—		6.6
Net (loss) income from continuing operations	(85.0)		0.7		9.4		12.9		(4.6)		0.3		16.4		58.9		18.9		6.2		9.2		43.3
Diluted EPS - Continuing Operations	($1.74)		$0.01		$0.19		$0.26		($0.09)		$0.01		$0.33		$1.18		$0.38		$0.13		$0.18		$0.87


GAAP results for the six months ended June 30, 2021 include:
(A)			Merger and integration expenses related to our legacy companies and recent acquisitions
(B)			Restructuring expenses related to organizational changes
(C)			Includes depreciation and amortization associated with purchase price accounting
(D)			Gain associated with the sale of Heart Valves
(E)			Costs related to the 3T Heater-Cooler remediation plan
(F)			Costs associated with our June 2020 financing transactions, including the mark-to-market adjustment for the exchangeable option feature and capped call derivatives
(G)			3T Heater-Cooler litigation provision, legal expenses primarily related to 3T Heater-Cooler defense, settlements, other matters, remeasurement of contingent consideration related to acquisitions, gain from remeasurement of an investment and dividend income
(H)			Non-cash expenses associated with stock-based compensation costs
(I)			Primarily relates to discrete tax items and the tax impact of intercompany transactions
(J)			Primarily relates to non-cash interest expense on our Senior Secured Term Loan and Cash Exchangeable Senior Notes
* Numbers may not add precisely due to rounding.


RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (U.S. dollars in millions, except per share amounts)
			Specified Items
Six Months Ended June 30, 2020	GAAP Financial Measures		Merger and Integration Expenses (A)		Restructuring Expenses (B)		Depreciation and Amortization Expenses (C)		Product Remediation Expenses (D)		Financing Transactions (E)		Certain Legal, Contingent Consideration and Other (F)		Stock-based Compensation Costs (G)		Certain Tax Adjustments (H)		Certain Interest Adjustments (I)		Adjusted Financial Measures
Cost of sales	$141.6		$—		$—		($10.9)		($5.7)		$—		$24.2		($0.9)		$—		$—		$148.3
Gross profit percent	66.6	%	—	%	—	%	2.6	%	1.4	%	—	%	(5.7)	%	0.2	%	—	%	—	%	65.1	%
Selling, general and administrative	227.7		—		—		(9.6)		—		(2.5)		(15.6)		(16.6)		—		—		183.4
Selling, general and administrative as a percent of net sales	53.6	%	—	%	—	%	(2.2)	%	—	%	(0.6)	%	(3.7)	%	(3.9)	%	—	%	—	%	43.2	%
Research and development	61.1		—		—		(0.1)		—		—		16.6		(1.5)		—		—		76.1
Research and development as a percent of net sales	14.4	%	—	%	—	%	—	%	—	%	—	%	3.9	%	(0.4)	%	—	%	—	%	17.9	%
Other operating expenses	8.9		(5.5)		(2.4)		—		—		—		(1.0)		—		—		—		—
Operating (loss) income from continuing operations	(14.6)		5.5		2.4		20.5		5.7		2.5		(24.3)		19.0		—		—		16.8
Operating margin percent	(3.4)	%	1.3	%	0.6	%	4.8	%	1.4	%	0.6	%	(5.7)	%	4.5	%	—	%	—	%	4.0	%
Income tax expense	21.6		0.3		—		2.9		0.8		—		2.0		0.6		(27.0)		—		1.2
Net (loss) income from continuing operations	(49.4)		5.2		2.4		17.6		5.0		2.7		(26.3)		18.4		27.0		6.0		8.5
Diluted EPS - Continuing Operations	($1.02)		$0.11		$0.05		$0.36		$0.10		$0.05		($0.54)		$0.38		$0.55		$0.12		$0.17


GAAP results for the six months ended June 30, 2020 include:
(A)			Merger and integration expenses related to our legacy companies and recent acquisitions
(B)			Restructuring expenses related to organizational changes
(C)			Includes depreciation and amortization associated with purchase price accounting
(D)			Costs related to the 3T Heater-Cooler remediation plan
(E)			Costs associated with our June 2020 financing transactions, including the mark-to-market adjustment for the exchangeable option feature and capped call derivatives
(F)			3T Heater-Cooler litigation provision, legal expenses primarily related to 3T Heater-Cooler defense, settlements and other matters, remeasurement of contingent consideration related to acquisitions
(G)			Non-cash expenses associated with stock-based compensation costs
(H)			Primarily relates to discrete tax items and the tax impact of intercompany transactions
(I)			Primarily relates to non-cash interest expense on our Senior Secured Term Loan and Cash Exchangeable Senior Notes, interest related to the 3T Heater-Cooler matter and intellectual property migration
* Numbers may not add precisely due to rounding.


LIVANOVA PLC AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED
(U.S. dollars in millions)
	June 30, 2021	December 31, 2020
ASSETS
Current Assets:
Cash and cash equivalents	$329.4	$252.8
Accounts receivable, net of allowance	182.2	184.4
Inventories	127.2	126.7
Prepaid and refundable taxes	36.2	60.2
Assets held for sale	—	70.5
Current derivative assets	105.4	2.1
Prepaid expenses and other current assets	28.8	22.7
Total Current Assets	809.1	719.4
Property, plant and equipment, net	157.4	163.8
Goodwill	918.3	922.3
Intangible assets, net	419.2	437.6
Operating lease assets	49.9	50.5
Investments	15.3	31.1
Deferred tax assets	1.9	3.0
Long-term derivative assets	—	72.3
Other assets	25.5	11.2
Total Assets	$2,396.5	$2,411.4
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Current debt obligations	$232.0	$13.3
Accounts payable	61.3	73.7
Accrued liabilities and other	100.2	88.0
Current derivative liabilities	174.9	7.4
Current litigation provision liability	53.2	28.6
Taxes payable	18.4	16.5
Accrued employee compensation and related benefits	62.2	51.9
Liabilities held for sale	—	29.7
Total Current Liabilities	702.2	309.1
Long-term debt obligations	431.0	642.3
Contingent consideration	97.0	89.9
Litigation provision liability	7.0	7.9
Deferred tax liabilities	10.5	8.9
Long-term operating lease liabilities	42.7	42.2
Long-term employee compensation and related benefits	18.4	20.6
Long-term derivative liabilities	0.2	121.9
Other long-term liabilities	47.0	49.7
Total Liabilities	1,356.1	1,292.5
Total Stockholders’ Equity	1,040.5	1,118.8
Total Liabilities and Stockholders’ Equity	$2,396.5	$2,411.4

* Numbers may not add precisely due to rounding.


LIVANOVA PLC AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED
(U.S. dollars in millions)	Six Months Ended June 30,
	2021	2020
Operating Activities:
Net loss	($85.0)	($50.4)
Non-cash items included in net loss:
Stock-based compensation	19.5	19.0
Amortization	13.4	19.7
Remeasurement of derivative instruments	13.2	(7.3)
Depreciation	12.3	13.6
Remeasurement of contingent consideration to fair value	10.7	(46.0)
Amortization of debt issuance costs	9.0	1.2
Amortization of operating lease assets	8.9	6.3

Remeasurement of Respicardia investment and loan	(4.6)	—




Deferred tax expense	1.4	46.2
Other	1.4	4.2
Changes in operating assets and liabilities:
Accounts receivable, net	(4.7)	66.3
Inventories	1.2	(16.2)
Other current and non-current assets	18.8	(10.3)
Accounts payable and accrued current and non-current liabilities	3.6	(48.0)
Taxes payable	2.5	(2.2)
Litigation provision liability	23.7	(121.2)

Net cash provided by (used in) operating activities	45.1	(125.1)
Investing Activities:
Purchases of property, plant and equipment	(14.6)	(18.0)
Purchase of investments	(2.1)	(3.2)
Proceeds from sale of Heart Valves, net of cash disposed	41.8	—
Proceeds from sale of Respicardia investment and loan	23.1	—
Loans to investees	—	(2.3)



Other	(1.4)	0.7
Net cash provided by (used in) investing activities	46.7	(22.7)
Financing Activities:
Shares repurchased from employees for minimum tax withholding	(11.1)	(5.2)
Payment of contingent consideration	(4.4)	(5.3)
Proceeds from share issuances under ESPP	1.8	2.1
Repayment of long-term debt obligations	(1.3)	(481.3)

Debt issuance costs	(0.4)	(20.0)
Change in short-term borrowing, net	0.1	(1.5)
Proceeds from long-term debt obligations	—	886.9
Proceeds from short term borrowings (maturities greater than 90 days)	—	46.7
Repayments of short term borrowings (maturities greater than 90 days)	—	(44.8)
Purchase of capped call	—	(43.1)
Closing adjustment payment for sale of CRM business	—	(14.9)
Other	1.2	—
Net cash (used in) provided by financing activities	(14.1)	319.7
Effect of exchange rate changes on cash and cash equivalents	(1.2)	(0.6)
Net increase in cash and cash equivalents	76.6	171.4
Cash and cash equivalents at beginning of period	252.8	61.1
Cash and cash equivalents at end of period	$329.4	$232.5

* Numbers may not add precisely due to rounding.


RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (U.S. dollars in millions)
		Three Months Ended June 30,		% Change at Actual Currency Rates		% Change at Constant-Currency Rates (1)
		2021	2020
GAAP net sales		$264.5	$182.2	45.2	%	41.0	%
Less Heart Valves net sales		14.7	17.5	(15.7)	%	(21.5)	%
Net sales excluding Heart Valves		$249.8	$164.7	51.6	%	47.6	%

(1)	Constant-currency growth, a non-GAAP financial measure, measures the change in sales between current and prior-year periods using average exchange rates in effect during the applicable prior-year period.
*	Numbers may not add precisely due to rounding.

The following table presents the reconciliation of GAAP diluted weighted average shares outstanding, used in the computation of GAAP diluted net loss per common share from continuing operations, to adjusted diluted weighted average shares outstanding, used in the computation of adjusted diluted earnings per common share from continuing operations (in millions of shares):


RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED (shares in millions)
		Three Months Ended June 30,		Six Months Ended June 30,
		2021	2020	2021	2020
GAAP diluted weighted average shares outstanding		48.9	48.6	48.8	48.5
Add effects of stock-based compensation instruments		0.9	—	0.9	0.3
Adjusted diluted weighted average shares outstanding (1)		49.8	48.6	49.7	48.8

(1)	Adjusted diluted weighted average shares outstanding is a non-GAAP measure and includes the effects of stock-based compensation instruments, as reconciled in the above table.
*	Numbers may not add precisely due to rounding.

EX-101.SCH 3 livn-20210728.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 livn-20210728_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Country Region Country Region Document Type Document Type Entity Address, Postal Zip Code Entity Address, Postal Zip Code Local Phone Number Local Phone Number Amendment Flag Amendment Flag Written Communications Written Communications City Area Code City Area Code Title of 12(b) Security Title of 12(b) Security Security Exchange Name Security Exchange Name Soliciting Material Soliciting Material Document Period End Date Document Period End Date Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Cover [Abstract] Cover [Abstract] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Country Entity Address, Country Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol EX-101.PRE 5 livn-20210728_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 downloada03.jpg begin 644 downloada03.jpg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end GRAPHIC 7 livn-20210728_g1.jpg begin 644 livn-20210728_g1.jpg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end XML 8 livn-20210728_htm.xml IDEA: XBRL DOCUMENT 0001639691 2021-07-28 2021-07-28 LIVANOVA PLC 0001639691 false 8-K 2021-07-28 X0 001-37599 98-1268150 20 Eastbourne Terrace London W2 6LG GB 44 20 33250660 false false false false Ordinary Shares - £1.00 par value per share LIVN NASDAQ false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2

Document and Entity Information Document

Jul. 28, 2021

Cover [Abstract]

Document Type 8-K

Document Period End Date Jul. 28, 2021

Entity Incorporation, State or Country Code X0

Entity File Number 001-37599

Entity Tax Identification Number 98-1268150

Entity Address, Address Line One 20 Eastbourne Terrace

Entity Address, City or Town London

Entity Address, Postal Zip Code W2 6LG

Entity Address, Country GB

Country Region 44

City Area Code 20

Local Phone Number 33250660

Written Communications false

Soliciting Material false

Pre-commencement Tender Offer false

Pre-commencement Issuer Tender Offer false

Title of 12(b) Security Ordinary Shares - £1.00 par value per share

Trading Symbol LIVN

Security Exchange Name NASDAQ

Entity Emerging Growth Company false

Entity Registrant Name LIVANOVA PLC

Entity Central Index Key 0001639691

Amendment Flag false

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Region code of country
+ References
No definition available.
+ Details

Name: dei_CountryRegion

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
ISO 3166-1 alpha-2 country code.
+ References
No definition available.
+ Details

Name: dei_EntityAddressCountry

Namespace Prefix: dei_

Data Type: dei:countryCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details

Name: dei_PreCommencementIssuerTenderOffer

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details

Name: dei_PreCommencementTenderOffer

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
+ Details

Name: dei_SolicitingMaterial

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details

Name: dei_WrittenCommunications

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 97 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Document and Entity Information Document Sheet http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports livn-20210728.htm a2q2021earningspressrelease.htm livn-20210728.xsd livn-20210728_lab.xml livn-20210728_pre.xml livn-20210728_g1.jpg http://xbrl.sec.gov/dei/2020-01-31 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "livn-20210728.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "livn-20210728.htm" ] }, "labelLink": { "local": [ "livn-20210728_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "livn-20210728_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "livn-20210728.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "livn", "nsuri": "http://www.livanova.cyberonics.com/20210728", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "livn-20210728.htm", "contextRef": "i760f85d1d991439b8739e913698f7228_D20210728-20210728", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information Document", "role": "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "livn-20210728.htm", "contextRef": "i760f85d1d991439b8739e913698f7228_D20210728-20210728", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region", "terseLabel": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.livanova.cyberonics.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001639691-21-000085-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001639691-21-000085-xbrl.zip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end

Document and Entity Information Document	Jul. 28, 2021
Cover [Abstract]
Document Type	8-K
Document Period End Date	Jul. 28, 2021
Entity Incorporation, State or Country Code	X0
Entity File Number	001-37599
Entity Tax Identification Number	98-1268150
Entity Address, Address Line One	20 Eastbourne Terrace
Entity Address, City or Town	London
Entity Address, Postal Zip Code	W2 6LG
Entity Address, Country	GB
Country Region	44
City Area Code	20
Local Phone Number	33250660
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Ordinary Shares - £1.00 par value per share
Trading Symbol	LIVN
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Registrant Name	LIVANOVA PLC
Entity Central Index Key	0001639691
Amendment Flag	false